TNFA (tnfpharma.com) Volume dodolan mangsa ngarep perusahaan

Logo perusahaan publik TNF Pharmaceuticals (TNFA)

TNF Pharmaceuticals possesses significant scientific weight in developing small-molecule treatments for fibrosis, while updated management has restructured R&D assets to target inflammation. The company's projected sales levels confirm these expectations, where the parameter mark equals 0.00. However, a lack of profitability and the risks of failed trials amid fierce competition create a threat of a decline in share value.

Prakiraan pendapatan perusahaan: TNF Pharmaceuticals (TNFA) kanggo 25.07.2024 - 25.09.2025

Rincian metrik keuangan lan pasar tnfpharma.com (TNFA)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental perusahaan:TNF Pharmaceuticals
Sampel barang TNF Pharmaceuticals

The development of oral TNF inhibitors and the success of the MYMD-1 drug determine the scaling potential of TNF Pharmaceuticals (TNFA). This sales revenue forecast correlates the current market value of TNF Pharmaceuticals (TNFA) with liquidity criteria and business volume. The price action reflects turnover instability prior to the release of official reports. The indicator's growth confirms the issuer's compliance with strict capitalization requirements, serving as the foundation for a long-term assessment of the assets' investment attractiveness.

Pesaing langsung

Prakiraan volume dodolan HLN|KVUE (Kenvue Inc) - Pendapatan mangsa ngarep perusahaan|Verona Pharma Corp - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan MENS (Jyong Biotech Ltd)|ligand.com - Prakiraan volume dodolan|amneal.com (AMRX) - Volume dodolan mangsa ngarep perusahaan|Perrigo (PRGO) - Prakiraan pendapatan perusahaan|ALVO (Alvotech S.A.) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan LQDA|Prakiraan volume dodolan Galapagos Corp|Prakiraan pendapatan perusahaan ANI Pharma (ANIP)|Prakiraan volume dodolan MannKind Corporation (MNKD)|Prakiraan pendapatan perusahaan Amphastar Pharmaceuticals Inc AMPH|Prakiraan volume dodolan Pacira PCRX|ARS Pharmaceuticals Inc - Prakiraan volume dodolan|TBPH - Prakiraan volume dodolan|AQST (Aquestive Therapeutics) - Volume dodolan mangsa ngarep perusahaan|scPharmaceuticals, Inc. (SCPH) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan TECX|Prakiraan volume dodolan Tonix Pharma|Volume dodolan mangsa ngarep perusahaan SXTC (SXT Pharmaceuticals)|EPRX: Pendapatan sing dikarepake perusahaan|BioHarvest Sciences - Volume dodolan mangsa ngarep perusahaan|EXOZ: Prakiraan pendapatan perusahaan|ORMP - Prakiraan pendapatan perusahaan|ENTX: Prakiraan pendapatan perusahaan|HYFT: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan ABVC BioPharma Inc|CPIX (Cumberland Corp) - Prakiraan volume dodolan|Prakiraan volume dodolan quantumbiopharma.com|Prakiraan volume dodolan FGEN|Volume dodolan mangsa ngarep perusahaan Telomir Pharmaceuticals, Inc. TELO|Prakiraan volume dodolan RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Pendapatan sing dikarepake perusahaan|RLYB: Volume dodolan mangsa ngarep perusahaan|lexariabioscience.com (LEXX) - Volume dodolan mangsa ngarep perusahaan|Pulmatrix Inc (PULM) - Prakiraan pendapatan perusahaan|PTHL: Prakiraan volume pendapatan perusahaan|APM (Aptorum Group Ltd) - Prakiraan volume dodolan|Lyra Therapeutics Inc (LYRA) - Dodolan mangsa ngarep perusahaan|Prakiraan volume dodolan IBO|Prakiraan volume dodolan cbdMD Corp (YCBD)|Prakiraan volume dodolan PRFX (PainReform)|Dodolan mangsa ngarep perusahaan Auris Medical (CYTO)|LIPO - Prakiraan pendapatan perusahaan|Optinose (OPTN) - Volume dodolan mangsa ngarep perusahaan|Pieris (PIRS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan PROC (Procaps Group S.A.)|Volume dodolan mangsa ngarep perusahaan PTPI|QLI: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan acelyrin.com (SLRN)|TFFP (TFF Pharma) - Pendapatan mangsa ngarep perusahaan